Connect with us

Technology

SOPHiA GENETICS Presents Ground-Breaking Multimodal Research on AI-Driven Patient Stratification at ESMO 2024

Published

on

Research highlights the use of multimodal machine learning to identify non-small cell lung cancer patients predicted to derive the most benefit from combination immunotherapy

BOSTON and ROLLE, Switzerland, Sept. 14, 2024 /PRNewswire/ — SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a leader in data-driven medicine, will unveil new research at the European Society for Medical Oncology (ESMO) 2024. The study, conducted in collaboration with AstraZeneca, leverages advanced AI-driven techniques to identify subgroups of stage IV non-small cell lung cancer (NSCLC) patients who could most benefit from the addition of tremelimumab to durvalumab and chemotherapy.

The research is a retrospective, multimodal analysis of the POSEIDON Phase 3 clinical trial (NCT03164616). This trial originally demonstrated that the combination of tremelimumab, durvalumab, and chemotherapy significantly increases progression-free survival (PFS) and overall survival (OS) versus chemotherapy in patients with metastatic NSCLC, which lead to approval of this regiment globally in 1L mNSCLC. The SOPHiA GENETICS study used cutting-edge multimodal machine learning models to analyze clinical, biological, genomic, and imaging data, pinpointing patient subgroups who are most likely to benefit from the combination treatment.

The research highlighted signatures identifying patients with non-squamous metastatic NSCLC who may derive higher OS benefit from the addition of tremelimumab to durvalumab plus chemotherapy in the first-line treatment setting. In particular, EGFR wild-type, FGFR3 wild-type, CDKN2A wild-type, KRAS mutation, and STK11 mutation comprised elements of a signature was identified as being associated with a higher OS benefit. These findings could have significant implications for the treatment of NSCLC, as it provides an exploration avenue towards a more tailored approach to patient care.

“Our collaboration with AstraZeneca represents a major step forward in personalized oncology. Non-small cell lung cancer remains one of the most challenging cancers to treat due to its complex biology and the late stage at which it is often diagnosed,” said Jurgi Camblong, Ph.D., Co-founder and CEO of SOPHiA GENETICS. “This study harnesses the power of multimodal data and advanced AI to identify which patients are most likely to benefit from specific therapies. By tailoring treatment strategies based on a patient’s unique multimodal profile, we aim to improve outcomes and offer new hope to those battling this difficult disease.”

The study will be presented as a poster by Ferdinandos Skoulidis, Department of Thoracic Medical Oncology, University of Texas MD Anderson Cancer Center at ESMO 2024 hosted in Barcelona, Spain from September 13-17, 2024. His presentation showcases the operational feasibility and clinical impact of large-scale multimodal analyses in identifying heterogeneous treatment effects in oncology.

For more information on SOPHiA GENETICS, visit SOPHiAGENETICS.COM, or connect on LinkedIn.

About SOPHiA GENETICS 
SOPHiA GENETICS (Nasdaq: SOPH) is a cloud-native healthcare technology company on a mission to expand access to data-driven medicine by using AI to deliver world-class care to patients with cancer and rare disorders across the globe. It is the creator of the SOPHiA DDM™ Platform, which analyzes complex genomic and multimodal data and generates real-time, actionable insights for a broad global network of hospital, laboratory, and biopharma institutions. For more information, visit SOPHiAGENETICS.COM and connect with us on LinkedIn.

SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact support@sophiagenetics.com to obtain the appropriate product information for your country of residence. 

SOPHiA GENETICS Forward-Looking Statements: 
This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy, products, and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of the date hereof. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/sophia-genetics-presents-ground-breaking-multimodal-research-on-ai-driven-patient-stratification-at-esmo-2024-302246192.html

SOURCE SOPHiA GENETICS

Continue Reading

Technology

WuXi Biologics Receives Double Honors at 2026 HERA for ESG Reporting and Environmental Excellence

Published

on

By

HONG KONG, Nov. 3, 2026 /PRNewswire/ — WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced it received two Grand Awards at the ninth Hong Kong ESG Reporting Awards (HERA), winning Best ESG Report (Large-Cap) and Excellence in Environmental Positive Impact.

HERA celebrates excellence in sustainability reporting and ESG practices, with award categories spanning ESG governance, environmental and social impact, carbon neutrality, and workplace well-being. The program is independently judged by a panel drawn from academia, finance, sustainability advisory and regulatory backgrounds, promoting transparency, accountability and stakeholder trust.

Selected from 120 entries, WuXi Biologics was the only pharmaceutical company to receive a Grand Award this year. Its two honors recognize WuXi Biologics’ continual efforts to advance transparent, high-quality ESG disclosure and deliver measurable environmental progress across its global operations.

Dr. Chris Chen, CEO of WuXi Biologics and Chairman of its ESG Committee, commented, “We are delighted to receive two HERA awards, which reflect our ongoing conviction that transparent ESG disclosure and strong environmental performance are integral to business resilience and long-term success. WuXi Biologics will continue to advance our ESG governance and Green CRDMO strategy, working with global partners to drive sustainable development across the value chain.”

Through its Green CRDMO solutions, the Company continues to embed sustainability principles throughout its biologics research, development, manufacturing, and operations. In 2025, WuXi Biologics’ near-term, long-term and net-zero greenhouse gas emissions reduction targets were validated by the Science Based Targets initiative (SBTi), covering Scope 1, 2 and 3 emissions and aligned with a 1.5°C pathway. Another honor WuXi Biologics recently received was being named to the 2026 Forbes China ESG 50 list for achievements in sustainable development, Green CRDMO solutions, and ESG digital innovation.

About WuXi Biologics

WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide*.

With over 14,000 employees in China, the United States, Ireland, Germany, and Singapore, including experts and scientists in biologics R&D and manufacturing, technology innovation, and operational excellence, WuXi Biologics leverages its technologies and expertise to deliver efficient, cost-effective, and scalable biologics solutions tailored to meet clients’ needs. By embedding digital capability and infrastructure across the full biopharmaceutical value chain, the company turns data, computation, and prediction into transparent client experience, faster development, intelligent operations, and more efficient manufacturing. As of June 30, 2026, WuXi Biologics is supporting 1064 integrated client projects, including 78 in Phase III and 28 in commercial manufacturing, with complex modalities representing more than half of the entire project portfolio.

WuXi Biologics regards sustainability as the cornerstone of long-term business growth. The company continuously drives technology innovations to offer advanced end-to-end Green CRDMO solutions for its global partners while demonstrating exemplary Environmental, Social and Governance (ESG) practices. Committed to creating shared value, it collaborates with all stakeholders to foster positive social and environmental impacts, and promote responsible practices that empower the entire value chain.

For more information about WuXi Biologics, please visit: www.wuxibiologics.com.

*The winner of the “2026 Biologics CDMO of the Year” (Large CDMOs) (Life Science Connect / Outsourced Pharma)

*The winner of the “2026 Best Contract Development & Manufacturing Organization Award” (ABEA)

Contacts

ESG
esg@wuxibiologics.com

Media
PR@wuxibiologics.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/wuxi-biologics-receives-double-honors-at-2026-hera-for-esg-reporting-and-environmental-excellence-302928803.html

SOURCE WuXi Biologics

Continue Reading

Technology

Only 54% of Consumers Trust That Black Friday Discounts Are Lower Than Normal as Promotion Fatigue Grows

Published

on

By

BCG’s Annual Black Friday Survey Finds 1 in 5 Consumers Actively Distrust Advertised Discounts22% Plan to Spend Less or Skip Year-End Sales EventsRetailer Reputation and Transparent Pricing Rank Among the Highest Factors for Building Consumer Trust; Influencer Recommendations Rank LastUse of Social Media as a Shopping Inspiration Source Falls 9 Points to 46%, While AI Rises Across All Surveyed Countries

BOSTON, Nov. 4, 2026 /PRNewswire/ — Only 54% of consumers trust that advertised Black Friday prices are genuinely lower than usual, and one in five actively distrust them, according to a new survey from Boston Consulting Group (BCG).

Promotion fatigue is also growing, with 22% of consumers planning to spend less or skip year-end sales events because they believe discounts are available all the time.

Despite growing skepticism around promotions, consumers haven’t raised the bar for what constitutes a good deal. The expected minimum discount for a good deal eased to about 30% (versus 32% in 2025).

These are among the findings of BCG’s sixth annual Black Friday Consumer Study, based on a survey of 10,220 consumers across ten countries. The report, titled For Year-End Sales Events, Trust Is the New Currency, examines shopping expectations and behaviors ahead of Singles’ Day, Black Friday, and Cyber Monday.

“Shoppers no longer take Black Friday discounts at face value. Nearly half are unconvinced that prices are actually lower,” said Nate Shenck, a BCG managing director and senior partner, and coauthor of the report. “Retailers can’t discount their way past that. The question this season is how to earn shoppers’ trust.”

Credibility and Proof Build Trust, Persuasion Does Not

BCG determined the factors that build consumer trust using a net trust score (calculated as the share of consumers who say a factor increases their trust in a deal, minus the share who say it decreases it):

Retailer reputation and money-back guarantees ranked highest, each with a net trust score of 65%Verified purchase reviews also ranked among the top trust builders (59%), followed by clear comparisons between regular and discounted prices (58%)At the bottom of the ranking, real-time scarcity messages scored just 8%, AI-generated review summaries 4%, and influencer recommendations only 3%

AI Is Displacing Social Media as an Inspiration Channel

Social media as an inspiration source for consumers declined nine percentage points to 46%, falling in every market surveyed, whereas AI as an inspiration source increased across all ten markets.

Planned AI usage reached 56% of shoppers this year, up eight points from 2025. Around 86% of users find it helpful, and 78% say it raises their likelihood of completing a purchase.

Consumers trust AI most for comparing prices across retailers (39%) and comparing product features (37%). Transactional tasks, such as filling in checkout details, are still developing as a common use case.

“Shoppers facing promotion fatigue are turning to AI to do the work of finding and comparing deals. AI is already beginning to replace influencers as a go-to source for inspiration,” said Jessica Distler, a BCG managing director and partner, and coauthor of the report. “That means retailers need to think as carefully about how their offers are found and verified as they do about the discounts themselves.”

Download the report here:
https://www.bcg.com/publications/2026/trust-matters-year-end-sales-events

Media Contact:
Kendall Kosten
kosten.kendall@bcg.com 

About Boston Consulting Group
Boston Consulting Group bridges the gap between ambition and outcomes for the world’s leading companies and organizations. We are built for this era of unprecedented change — bringing strategic clarity rooted in over 60 years of deep domain knowledge, combined with applied AI shaped by our practitioners. BCG works shoulder-to-shoulder with CEOs across industries and geographies to deliver transformative impact at scale: stronger returns, transferred capabilities, and change that sticks. For more information, visit bcg.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/only-54-of-consumers-trust-that-black-friday-discounts-are-lower-than-normal-as-promotion-fatigue-grows-302928764.html

SOURCE Boston Consulting Group (BCG)

Continue Reading

Technology

Most Robots Still Aren’t Insured. YAS and Robolist Are Changing That.

Published

on

By

YAS and Robolist.ai partner to bring a free Risk Score and a path to insurance to robotics companies, giving firms, investors, and buyers a safer, more transparent foundation for an industry entering mass production

HONG KONG, Nov. 4, 2026 /PRNewswire/ — Artificial intelligence’s next phase is getting a body. Humanoid robot shipments are up sharply in 2026, with global shipments reaching roughly 30,000 units in the first half of the year alone, nearly 300% higher than a year earlier. But humanoids are only the headline category. Robolist.ai (“Robolist”), an independent market intelligence layer for robotics used by investors worldwide, tracks more than 4,200 robots from over 1,300 manufacturers across categories including industrial arms, warehouse AMRs, cobots, commercial cleaning, delivery, hospitality, and home robots, and growth is accelerating across nearly all of them.

Across every one of those categories, most of what is shipping today carries no insurance. YAS, a data risk intelligence platform that helps insurers underwrite EV, robotaxi, and now robotics risk, today announced a strategic partnership with Robolist to close that gap — starting with a free Risk Score for the companies Robolist already ranks, and a path to coverage for those who want one.

Putting safety first, for an industry still finding its footing

Robotics is moving from pilots to mass production, and that shift changes who is exposed and what’s at stake. YAS and Robolist both see the same underlying problem: an industry growing faster than the risk infrastructure built to support it. Pairing YAS’s risk intelligence with Robolist’s independent market data gives the industry one more layer of transparency, a shared, safety-first foundation that the companies believe is necessary for robotics to grow into a trusted, durable category rather than a fast-moving one with uneven guardrails.

What it means for robotics firms

Every manufacturer listed on Robolist is already independently ranked. Starting with this partnership, any of them can also request a free Risk Score, built with YAS, covering their systems across whichever category they operate in, not just humanoid. A strong, transparent risk profile is becoming a competitive advantage in its own right, a signal to enterprise buyers and partners that a company takes safety seriously. There is no cost to check it and no obligation attached.

What it means for investors

Robolist’s independent data has always given investors a clear picture of what a company has actually raised and shipped. Adding YAS’s Risk Score introduces a second, forward-looking signal: a working estimate of operational risk exposure, sitting alongside funding and deployment evidence. Together, the two offer a more complete basis for diligence, and support the kind of informed, patient capital that helps the category grow in a healthy, sustainable way rather than on hype alone.

What it means for buyers

Enterprises deciding whether to deploy a robot fleet have historically had almost no independent way to compare risk across vendors. The Risk Score gives buyers a transparent reference point alongside Robolist’s existing rankings, and a direct route to insurance for the deployments they choose to move forward with, so adoption decisions can be made with more confidence and less guesswork.

Status

The partnership is in its exploratory phase under a signed Memorandum of Understanding, beginning with Hong Kong, with other markets under consideration as it develops. The Risk Score is an indicative analytical tool, not a safety certification or a guarantee of coverage; insurance, where available, is issued by licensed carriers.

Quotes

“Robotics is scaling faster than the risk infrastructure around it. You can’t insure what you can’t measure — so we start by measuring. A free Risk Score, built on live operating data, gives every robotics company a transparent read on their exposure and, when they want it, a path to coverage. That’s how a fast-moving category becomes a durable one.”— Andy Ann, Founder, YAS

“We built Robolist as an independent market intelligence layer for robotics. Partnering with YAS deepens that layer. There’s a lot of natural overlap between what we do. Robotics insurance is a long-term project that benefits everyone in the industry, and it matters more now that the category is moving into mass production. Part of that is simply caring about what happens to the people and businesses actually using these machines.” — Matthew Cheung, Co-founder, Robolist.ai

About YAS

YAS is a Hong Kong-based risk intelligence platform for the machine economy, turning live operating data from vehicles, fleets, and robots into real-time risk scores used by licensed insurers to underwrite fairer, faster coverage. YAS works with insurance carrier partners across robotics and humanoids, EV and commercial fleets, with autonomous vehicles next.

About Robolist.ai

Robolist.ai is an independent market intelligence layer for robotics, used by investors to track what manufacturers actually raise, ship, and deploy. Robolist tracks more than 4,200 robots from over 1,300 manufacturers across categories from humanoids and industrial arms to cleaning, delivery, and home robots.

Learn more

Manufacturers can claim their profile and request a free Risk Score, and investors and buyers can explore the data, at robolist.ai. To learn more about YAS’s risk intelligence platform, visit yas.io.

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/most-robots-still-arent-insured-yas-and-robolist-are-changing-that-302928742.html

SOURCE YAS

Continue Reading

Trending